Printer Friendly

INTRODUCTION OF GENERIC PARKINSON DRUG TO HELP PATIENTS AND PROVINCIAL GOVERNMENTS

 TORONTO, May 10 /PRNewswire/ -- Apotex Inc., the largest Canadian- owned pharmaceutical company announced today that it will soon be launching the first generic version of Eldepryl(R). Eldepryl(R) is one of the few drugs available for the treatment of Parkinson's disease and is manufactured by Deprenyl Research Limited.
 In a press release dated May 3, 1993 Deprenyl stated that its drug would be protected for up to 30 months by regulations pursuant to the recent Patent Act Changes (Bill C-91).
 "The Deprenyl patent is limited to a particular process; we use another process which does not infringe and therefore nothing stops us from selling a generic version. The press release by Deprenyl is thus without any basis" stated Apotex President, Dr. Barry Sherman.
 The Apotex product will be approximately priced 30 per cent to 40 percent lower and Apotex expects to capture at least half the market within the first year.
 Apotex produces over 100 generic drugs and has several new innovative drugs under development for the AIDS, Asthma and Cancer areas. It exports its products to almost 100 countries around the globe.
 -0- 5/10/93
 /CONTACT: Elie Betito, director of public and government affairs of Apotex Inc., 416-749-9300/


CO: Apotex Inc. ST: Ontario IN: MTC SU: PDT

SM -- NY062 -- 6489 05/10/93 12:17 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 10, 1993
Words:219
Previous Article:A. L. LABORATORIES NAMES CYRILL SIEWERT AS ORAL HEALTH CARE PRESIDENT
Next Article:MONRO REPORTS FOURTH QUARTER AND ANNUAL EARNINGS
Topics:


Related Articles
DEPRENYL RESEARCH LIMITED ANNOUNCES ELDEPRYL(R) LISTED ON THE ONTARIO DRUG BENEFIT FORMULARY
Red Tape Suffocating Canadian Health Care. (News Briefs/Nouvelles en Bref).
Experts divided on generic biologics.
Study Showed AGILECT(R) Improved Motor Fluctuations and Parkinson's Disease Symptoms in Levodopa-Treated Patients.
Initiation of Largest Disease Modification Trial to Study Effect of AGILECT(R) in Slowing Progression of Parkinson's Disease.
New Analyses Further Support Benefits of Once-Daily AZILECT(R) in the Treatment of Both Early and More Advanced Parkinson's Disease.
Generic versions of ropinirole OK'd for restless legs syndrome.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters